Search

Your search keyword '"Moum, B."' showing total 13 results
Start Over Author "Moum, B." Publisher wiley
13 results on '"Moum, B."'

1. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Author

Goll, G. L., primary, Jørgensen, K. K., additional, Sexton, J., additional, Olsen, I. C., additional, Bolstad, N., additional, Haavardsholm, E. A., additional, Lundin, K. E. A., additional, Tveit, K. S., additional, Lorentzen, M., additional, Berset, I. P., additional, Fevang, B. T. S., additional, Kalstad, S., additional, Ryggen, K., additional, Warren, D. J., additional, Klaasen, R. A., additional, Asak, Ø., additional, Baigh, S., additional, Blomgren, I. M., additional, Brenna, Ø., additional, Bruun, T. J., additional, Dvergsnes, K., additional, Frigstad, S. O., additional, Hansen, I. M., additional, Hatten, I. S. H., additional, Huppertz‐Hauss, G., additional, Henriksen, M., additional, Hoie, S. S., additional, Krogh, J., additional, Midtgard, I. P., additional, Mielnik, P., additional, Moum, B., additional, Noraberg, G., additional, Poyan, A., additional, Prestegård, U., additional, Rashid, H. U., additional, Strand, E. K., additional, Skjetne, K., additional, Seeberg, K. A., additional, Torp, R., additional, Ystrøm, C. M., additional, Vold, C., additional, Zettel, C. C., additional, Waksvik, K., additional, Gulbrandsen, B., additional, Hagfors, J., additional, Mørk, C., additional, Jahnsen, J., additional, and Kvien, T. K., additional

Published
2019
Full Text
View/download PDF

2. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis

Author

Nielsen, M. J., primary, Thorburn, D., additional, Leeming, D. J., additional, Hov, J. R., additional, Nygård, S., additional, Moum, B., additional, Saffioti, F., additional, Gilja, O. H., additional, Boberg, K. M., additional, Mazza, G., additional, Røsjø, H., additional, Pinzani, M., additional, Karlsen, T. H., additional, Karsdal, M. A., additional, and Vesterhus, M., additional

Published
2018
Full Text
View/download PDF

3. Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines

Author

Gomollón, F., primary, Chowers, Y., additional, Danese, S., additional, Dignass, A., additional, Haagen Nielsen, O., additional, Lakatos, P. L., additional, Lees, C. W., additional, Lindgren, S., additional, Lukas, M., additional, Mantzaris, G. J., additional, Michetti, P., additional, Moum, B., additional, Peyrin-Biroulet, L., additional, Toruner, M., additional, van der Woude, J., additional, Weiss, G., additional, Stoevelaar, H., additional, and Reinisch, W., additional

Published
2014
Full Text
View/download PDF

4. The management of iron deficiency in inflammatory bowel disease - an online tool developed by the RAND/UCLA appropriateness method

Author

Reinisch, W., primary, Chowers, Y., additional, Danese, S., additional, Dignass, A., additional, Gomollón, F., additional, Haagen Nielsen, O., additional, Lakatos, P. L., additional, Lees, C. W., additional, Lindgren, S., additional, Lukas, M., additional, Mantzaris, G. J., additional, Michetti, P., additional, Moum, B., additional, Peyrin-Biroulet, L., additional, Toruner, M., additional, van der Woude, J., additional, Weiss, G., additional, and Stoevelaar, H., additional

Published
2013
Full Text
View/download PDF

8. Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis

Author

ODES, S., primary, VARDI, H., additional, FRIGER, M., additional, ESSER, D., additional, WOLTERS, F., additional, MOUM, B., additional, WATERS, H., additional, ELKJAER, M., additional, BERNKLEV, T., additional, TSIANOS, E., additional, O’MORAIN, C., additional, STOCKBRÜGGER, R., additional, MUNKHOLM, P., additional, and LANGHOLZ, E., additional

Published
2009
Full Text
View/download PDF

12. Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue.

Author

Jelsness-Jørgensen LP, Frigstad SO, Moum B, Grimstad T, Opheim R, Jahnsen J, and Bernklev T

Abstract

Background: Pain has been associated with fatigue in many chronic diseases, but data are not available for inflammatory bowel disease (IBD). The aim of this study was to investigate whether fatigue is associated with pain in IBD after adjusting for the relevant covariates., Methods: Participants were recruited from nine hospitals in the south-eastern and western part of Norway. Socio-demographic variables were self-reported by patients. Disease activity was assessed by disease activity indices and faecal calprotectin. Patient-reported outcomes (PROs) were collected using the Fatigue Questionnaire (FQ), Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS) and Basic Nordic Sleep Questionnaire., Results: From a total of 452 invited patients, 414 (91.6%) provided written informed consent. After excluding any missing data, 408 total patients were included in the analyses (ulcerative colitis = 180 and Crohn's disease = 228). In the crude analysis, substantial and chronic fatigue were associated with increased pain intensity regardless of the diagnosis. However, when controlling for relevant covariates in the ANCOVA, the differences in pain intensity among patients with and without substantial or chronic fatigue were insignificant. The Cohen's d effect size was small to moderate (>0.20) in patients with chronic fatigue., Conclusions: Despite a tendency of elevated pain intensity scores among patients with fatigue, these differences were insignificant after controlling for the relevant covariates. However, based on Cohen's effect size, these differences may be of clinical importance in a subset of patients.

Published
2017
Full Text
View/download PDF

13. Elevated trimethylamine- N -oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function.

Author

Kummen M, Vesterhus M, Trøseid M, Moum B, Svardal A, Boberg KM, Aukrust P, Karlsen TH, Berge RK, and Hov JR

Abstract

Background: Trimethylamine- N -oxide (TMAO) is produced in the liver from trimethylamine, which is exclusively generated by gut bacteria., Objective: The objective of this article is to investigate the relationship between TMAO and primary sclerosing cholangitis (PSC) and its clinical characteristics., Methods: Serum TMAO was measured in 305 PSC patients, 90 ulcerative colitis patients and 99 healthy controls., Results: In PSC patients with normal liver function ( n  = 197), TMAO was higher in patients reaching liver transplantation or death during follow-up than those who did not, with an optimal TMAO cut-off of 4.1 µM (AUC = 0.64, p  < 0.001). PSC patients with high TMAO (>4.1 µM, n  = 77) exhibited shorter transplantation-free survival than patients with low TMAO ( n  = 120, log-rank test: p  < 0.0001). High TMAO (>4.1 µM) was associated with reduced transplantation-free survival (HR 1.87, p  = 0.011), independently of the Mayo risk score (HR 1.74, p  < 0.001). Overall, PSC patients demonstrated reduced TMAO values compared with ulcerative colitis and healthy controls, mainly caused by PSC patients with reduced liver function (INR > 1.2), suggesting impaired oxidation of trimethylamine to TMAO. PSC patients with and without inflammatory bowel disease had similar TMAO levels., Conclusion: In PSC patients with normal liver function, elevated TMAO was associated with shorter transplantation-free survival, potentially reflecting clinically relevant metabolic changes resulting from dietary interactions with the gut microbiota.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results